Article
Statin-dye conjugates for selective targeting of <i>KRAS</i> mutant cancer cells
2025-06-06
Abstract excerpt
<h4>ABSTRACT</h4> Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations ( KRAS MUT ), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS -transformed cells, prompting the question of whether statins could achieve selective uptake specifically in KRAS MUT cells. To investigate this...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9bf3ad81-6eb3-51a0-981d-c974a7ee53a6
- DOI
- 10.1101/2025.06.03.657329
